Compare · BDX vs LNSR
BDX vs LNSR
Side-by-side comparison of Becton Dickinson and Company (BDX) and LENSAR Inc. (LNSR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and LNSR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 614.5x LNSR ($67.8M).
- Over the past year, BDX is down 12.8% and LNSR is down 57.5% - BDX leads by 44.8 points.
- LNSR has been more active in the news (13 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 3 for LNSR).
- Company
- Becton Dickinson and Company
- LENSAR Inc.
- Price
- $150.47-0.49%
- $5.54-1.86%
- Market cap
- $41.65B
- $67.8M
- 1M return
- -1.79%
- +4.23%
- 1Y return
- -12.76%
- -57.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 13
- Recent ratings
- 25
- 3
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
LENSAR Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest LNSR
- Director Hammer Todd B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Director Ellis Thomas B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Principal Accounting Officer Wong Kendra was granted 13,066 shares, increasing direct ownership by 30% to 56,481 units (SEC Form 4)
- Chief Operating Officer Connaughton Alan B. was granted 34,843 shares, increasing direct ownership by 10% to 389,173 units (SEC Form 4)
- Chief Executive Officer Curtis Nicholas T was granted 130,662 shares, increasing direct ownership by 13% to 1,122,758 units (SEC Form 4)
- Director Weisner Aimee S was granted 17,421 shares, increasing direct ownership by 19% to 110,368 units (SEC Form 4)
- Director O'Farrell Elizabeth G. was granted 17,421 shares, increasing direct ownership by 35% to 67,368 units (SEC Form 4)
- Director Winer Gary M was granted 17,421 shares, increasing direct ownership by 20% to 105,635 units (SEC Form 4)
- Director Lindstrom Richard L Md was granted 17,421 shares, increasing direct ownership by 7% to 263,831 units (SEC Form 4)
- Director Link William J Phd was granted 17,421 shares, increasing direct ownership by 3% to 568,062 units (SEC Form 4)